Its radiobiological profile addresses limitations of traditional β-emitters, particularly for micrometastatic disease, and offers the potential for durable tumour control in PSMA-positive prostate cancer (Figure 1) [20,21,22]. This evidence concerns the gene FOLH1 and neoplasm.